HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NBP
NovaBridge Biosciences
There isn't enough reported data to score NBP yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NBP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NBP PE Valuation
NBP has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NBP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NBP's losses to grow, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.22 | -$0.10 |
| Q4 2024 | -$0.12 | +$1.03 |
| Q4 2023 | -$1.15 | +$2.33 |
| Q4 2022 | -$3.48 | -$1.48 |
| Q4 2021 | -$2.00 | -725% |
NBP has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NBP in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NBP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $4.1M | -91% |
| Q4 2022 | $47.8M | +262% |
| Q4 2019 | $4.5M | +189% |
NBP's revenue is growing: $4M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -5302% | -2650 points |
| Q4 2022 | 0% | N/A |
| Q2 2022 | -2019% | +2821 points |
| Q4 2021 | -2652% | -1270 points |
| Q4 2019 | -4840% | -3744 points |
| Q4 2018 | -1383% | N/A |
| Q3 2018 | -587% | N/A |
| Q2 2018 | -1096% | N/A |
NBP's operating margin was −5302% last quarter, down 462 points from the same quarter a year ago, near the bottom of its range since 2018.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
NBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$14.6M | +$38.1M |
| Q4 2024 | -$52.7M | +$144.8M |
| Q4 2023 | -$197.5M | +$126.2M |
| Q4 2022 | -$323.7M | -$173.2M |
| Q4 2021 | -$150.5M | -199% |
| Q4 2020 | $152M | +$284.1M |
| Q4 2019 | -$132.1M | -$112.1M |
NBP has burned cash in most quarters: −$73M over the past year, against −$610M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NBP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -17% | -44.9M shares |
| 1 year | +15% | +28.8M shares |
| 3 years | +279% | +162M shares |
NBP has 220M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | $335,000 |
| Q4 2023 | $9.2M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q4 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $5.2M |
| Q4 2018 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NBP Net Leverage
NBP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.9 | Oversold |
| Stochastic | 2.9 | Oversold |
NBP's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NBP PE vs Healthcare Sector
| Metric | NBP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NBP has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.21 | 31% below |
| 20 week MA | $1.57 | 47% below |
| 50 week MA | $2.36 | 65% below |
| 100 week MA | $2.35 | 65% below |
| 200 week MA | $2.26 | 63% below |
NBP is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NBP on returns for 2026, with the stronger performance.
NBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.5 | $41.6 | +232% |
| 2021 | $41.6 | $46.9 | +13% |
| 2022 | $46.9 | $3.48 | -93% |
| 2023 | $3.48 | $1.90 | -45% |
| 2024 | $1.90 | $0.88 | -54% |
| 2025 | $0.88 | $4.34 | +393% |
| 2026 YTD | $4.34 | $0.83 | -81% |
NBP's yearly returns have swung widely, from +393% in 2025 to −93% in 2022. It's down 81% so far in 2026.